Vision / R&D
Leadership
Finance / Economy
Talent / People / Culture
Innovation / Livability
Smart policies / Tax incentives
Sustainability
Social impact
| Number of employees | 70.6K |
|---|
| Products | Nexium® (esomeprazole), Onglyza® (saxagliptin), Oxis® Turbohaler (formoterol), Lynparza® (olaparib), Plendil® (felodipine), Pulmicort® (budesonide), Qtern® (dapagliflozin/saxagliptin), Seroquel XL® (quetiapine). |
|---|
| Operating Status | Active |
|---|
| Headquarters | Cambridge, Cambridgeshire, United Kingdom |
|---|
| Type | Health Technology |
|---|
| Established | 1999 |
|---|
| Net Income | US$1.227 billion (2019) |
|---|
| Revenue | US$24.384 billion (2019) |
|---|
| Industry/Categories | Health Technology |
|---|
| Traded as | AZN |
|---|
Own or work here?Summary
AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
History
AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK – two companies with similar science-based cultures and a shared vision of the pharmaceutical industry.
The merger aimed to improve the combined companies’ ability to deliver long term growth and enduring shareholder value through:
Vision
Our commitment to making a meaningful difference to patient health is founded on innovative science.
Mission
AstraZeneca’s mission is to create a meaningful difference in the lives of the patients we serve and the people who work here.
References
https://www.astrazeneca.co.uk/medicines-AZ.html
https://www.companieshistory.com/astrazeneca
https://www.comparably.com/companies/astrazeneca-plc/mission
https://en.wikipedia.org/wiki/AstraZeneca
https://pharmaphorum.com/views-analysis-sales-marketing/a_history_of-_astrazeneca/
Member/Partner of
